IPP Bureau
Briefs: Medicamen Biotech, Aurobindo Pharma and Ajooni Biotech
By IPP Bureau - September 12, 2024
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
India approves health insurance cover of Rs 5 lakh for all aged 70 years and above
By IPP Bureau - September 12, 2024
This aims to benefit approximately 4.5 crore families with six crore senior citizens with Rs. 5 lakh free health insurance cover on a family basis
Ayush Ministry resolves 1346 Public Grievances under the Special Campaign 3.0
By IPP Bureau - September 12, 2024
Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
Merck launches single-use reactor to accelerate ADC manufacturing
By IPP Bureau - September 12, 2024
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
AGC and Medinet sign agreement for cell therapy CDMO business
By IPP Bureau - September 12, 2024
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington
By IPP Bureau - September 11, 2024
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
By IPP Bureau - September 11, 2024
ALS patients experience neuroinflammation and rapid neurodegeneration
Evonik starts operation of new spray drying facility for pharmaceutical oral excipients
By IPP Bureau - September 11, 2024
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
NHA and IIT Kanpur sign MoU for development of digital public goods for AI in healthcare
By IPP Bureau - September 11, 2024
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
Pfizer highlights diverse oncology portfolio and combination approaches at ESMO 2024
By IPP Bureau - September 11, 2024
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Merck announces positive top-line results from Phase 3 trial evaluating efficacy and safety of Gardsil 9
By IPP Bureau - September 11, 2024
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Health Ministry releases "Health Dynamics of India (Infrastructure and Human Resources) 2022-23"
By IPP Bureau - September 10, 2024
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
Atal Innovation Mission, NITI Aayog hosts 20th MedTech Mitra Technical advisory meeting
By IPP Bureau - September 10, 2024
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
Presence of Mpox virus of West African clade 2 confirmed in isolated patient
By IPP Bureau - September 10, 2024
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial
By IPP Bureau - September 10, 2024
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
